Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 abiraterone abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy theranostics
Latest Posts
- Newsletter 11/2026 March 15, 2026
- Blood Lipid Profiles in Metastatic Prostate Cancer: A Window into Tumor Metabolism and Response to Enzalutamide March 14, 2026
- Organoids from Routine TUR‑P Samples: A Personalized Platform for Prostate Cancer Therapy Testing March 13, 2026
- Estrogen‑Based Androgen Suppression Plus ARSI in Prostate Cancer: A Phase 2 Quality‑of‑Life Trial March 13, 2026
An add-on strategy to maximize workouts: electro stimulation works for cancer patients
/in Clinical Trial, Metastatic/by MaxHopefully a Breakthrough: CLSP-1025 Targets Common p53 Mutation, Paving New Path for Solid Tumor Immunotherapy
/in Immunotherapy, Not PCa related, Preclinical Research/by MaxUnlocking the Fortress: Good News for Immunotherapy Directed to Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1/by MaxAnother AlphaFold evolution: Using AI to Identify Better Antibody Therapies
/in Artificial Intelligence, Not PCa related/by MaxAlphaFold keeps rocking: a new AI tool that can predict large proteins
/in Artificial Intelligence/by MaxBreakthrough discovery (in vitro): selective MMP7 inhibitor for cancer treatment
/in Not PCa related, Preclinical Research/by MaxOnchilles Pharma’s (potentially) Groundbreaking Pan-Cancer Therapeutics: Targeting the ELANE Pathway
/in Immunotherapy, Preclinical Research/by MaxEarly PSA Response as a Predictor and Mediator of Treatment Efficacy in Metastatic Hormone Sensitive Prostate Cancer
/in Post-hoc, Retrospective studies/by Max